Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Sells $135,032.24 in Stock

Alphatec Holdings, Inc. (NASDAQ:ATEC) CEO Patrick Miles sold 12,691 shares of the business’s stock in a transaction on Friday, March 7th. The stock was sold at an average price of $10.64, for a total value of $135,032.24. Following the completion of the sale, the chief executive officer now directly owns 5,857,603 shares in the company, valued at $62,324,895.92. This represents a 0.22 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Patrick Miles also recently made the following trade(s):

• On Wednesday, February 26th, Patrick Miles sold 32,393 shares of Alphatec stock. The stock was sold at an average price of $10.89, for a total value of $352,759.77.
• On Wednesday, February 5th, Patrick Miles sold 43,459 shares of Alphatec stock. The shares were sold at an average price of $11.95, for a total transaction of $519,335.05.
• On Wednesday, January 29th, Patrick Miles sold 50,000 shares of Alphatec stock. The stock was sold at an average price of $12.03, for a total transaction of $601,500.00.
• On Tuesday, January 21st, Patrick Miles sold 6,687 shares of Alphatec stock. The stock was sold at an average price of $12.00, for a total value of $80,244.00.

Alphatec Price Performance

Shares of ATEC stock opened at $10.46 on Friday. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15. The stock’s fifty day simple moving average is $10.88 and its 200 day simple moving average is $8.56. Alphatec Holdings, Inc. has a one year low of $4.88 and a one year high of $14.88. The firm has a market cap of $1.51 billion, a price-to-earnings ratio of -8.17 and a beta of 1.39.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.04). The firm had revenue of $176.79 million for the quarter, compared to analyst estimates of $172.74 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. On average, analysts expect that Alphatec Holdings, Inc. will post -1.08 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. Piper Sandler lifted their price target on Alphatec from $12.00 to $13.00 and gave the stock an “overweight” rating in a research note on Thursday, February 27th. Barclays lifted their target price on shares of Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Wednesday, January 22nd. StockNews.com raised shares of Alphatec from a “sell” rating to a “hold” rating in a research note on Friday, February 28th. Needham & Company LLC restated a “buy” rating and issued a $16.00 target price on shares of Alphatec in a report on Thursday, February 27th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Alphatec in a research note on Tuesday, January 14th. Two analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $17.67.

Institutional Trading of Alphatec

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Lido Advisors LLC raised its position in Alphatec by 8.4% in the 4th quarter. Lido Advisors LLC now owns 12,247 shares of the medical technology company’s stock worth $112,000 after purchasing an additional 953 shares during the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Alphatec by 0.4% in the 4th quarter. PNC Financial Services Group Inc. now owns 312,954 shares of the medical technology company’s stock worth $2,873,000 after purchasing an additional 1,120 shares during the last quarter. Comerica Bank increased its holdings in Alphatec by 66.8% in the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock valued at $29,000 after purchasing an additional 1,248 shares during the last quarter. Summit Investment Advisors Inc. grew its position in shares of Alphatec by 14.1% during the 4th quarter. Summit Investment Advisors Inc. now owns 10,890 shares of the medical technology company’s stock worth $100,000 after buying an additional 1,342 shares during the period. Finally, Atria Investments Inc raised its position in shares of Alphatec by 8.0% in the 3rd quarter. Atria Investments Inc now owns 19,609 shares of the medical technology company’s stock valued at $109,000 after acquiring an additional 1,460 shares during the period. 66.35% of the stock is currently owned by institutional investors and hedge funds.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.